Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 5

1.

The rosiglitazone decision process at FDA and EMA. What should we learn?

Pouwels KB, van Grootheest K.

Int J Risk Saf Med. 2012;24(2):73-80. doi: 10.3233/JRS-2012-0559.

PMID:
22751189
[PubMed - indexed for MEDLINE]
2.

After avandia: the use of antidiabetic drugs in patients with heart failure.

Khalaf KI, Taegtmeyer H.

Tex Heart Inst J. 2012;39(2):174-8. Review.

PMID:
22740727
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Diabetes drug safety update: Avandia and your heart.

[No authors listed]

Johns Hopkins Med Lett Health After 50. 2010 Jun;22(4):1-2, 7. No abstract available.

PMID:
20572316
[PubMed - indexed for MEDLINE]
4.

The painful truth.

Nissen SE.

Eur Heart J. 2010 May;31(10):1284-5. doi: 10.1093/eurheartj/ehq126. Epub 2010 Apr 23. No abstract available.

PMID:
20418344
[PubMed - indexed for MEDLINE]
Free Article
5.

Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.

Starner CI, Schafer JA, Heaton AH, Gleason PP.

J Manag Care Pharm. 2008 Jul-Aug;14(6):523-31.

PMID:
18693776
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk